Acadia pharmaceuticals announces closing of sale of rare pediatric disease priority review voucher for $150 million

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced the closing of the sale of its rare pediatric disease priority review voucher (prv) for $150 million before fees and expenses. as described at the time the agreement to sell was announced on november 5, 2024, acadia is required to pay neuren pharmaceuticals limited one-third of the net proceeds, pursuant to a license agreement between the companies. acadia plans to invest proceeds from the sale of the prv to.
ACAD Ratings Summary
ACAD Quant Ranking